Skip to main content

Table 1 Clinical and demographical features of three patients

From: Case series of intravenous thrombolysis for acute ischemic stroke in confirmed COVID-19 patients: single-centre experience

 

Patient 1

Patient 2

Patient 3

Age

62

59

58

Sex

Male

Female

Female

Patient history

 Pre-stroke mRS (0–5)

0

0

0

 Comorbidities

Hypertension, prediabetic

Hypertension, Diabetic, Obesity

Hypertension, Obesity

 Antiplatelet/anticoagulant

No

No

No

COVID-19 characteristics

 Nasopharyngeal swab

Positive

Positive

Positive

 Chest X-ray

Viral pneumonia characteristics (bilateral)

Viral pneumonia characteristics (bilateral)

Viral pneumonia characteristics (bilateral)

 Fever

No

Yes

No

 Cough

Yes

No

No

 Dyspnea

No

Yes

Yes

 Myalgia

No

No

No

 Gastrointestinal symptoms

No

No

No

 Pharmacological treatment

Favipiravir, antibiotic therapy; Levofloxasin, Azithromycin and enoxoparin 40 mg once daily

Favipiravir, antibiotic therapy; Levofloxasin, Ceftriaxone and enoxoparin 40 mg once daily

Favipiravir, antibiotic therapy; Levofloxasin, Ceftriaxone. Enoxoparin (-)

 IV tPA

Yes (80% of the total IV tPA dose)

Yes

Yes (80% of the total IV tPA dose)

 Initial SpO2 (room air)

90%

80%

93%

 Oxygen therapy

Nasal Cannule

NRB

NRB

Laboratory findings

 Haemaglobin, g/dl

15.4

11

13.8

 Leucocyte × 109/L

7.7

10.2↑

11.8↑

 Platelets × 109/L

538↑

516↑

314

 Neutrophils, %

71↑

89↑

78↑

 Lymphocytes, %

12↓

6↓

15↓

 aPTT, s

26

27

28.1

 PT, s

13.4

13.8

13.4

 INR

0.94

0.97

0.92

 Fibrinogen, mg/dl

473↑

655↑

423↑

 D-dimer, ng/ml

1710↑

> 20,000↑

910↑

 AST, U/L

31

13

15

 ALT, U/L

58↑

18

9

 Creatinine, mg/dl

–

0,4

0.8

 Glucose, mg/dl

168↑

410↑

140

 LDH, U/L

–

813↑

–

 CRP, mg/dl

0.7

8.3↑

2.9↑

Stroke features

 Clinical symptoms

Right hemiparesis, aphasia

Left hemiparesis, dysarthria

Right hemiparesis,dysarthria

 NIHSS at baseline

12

10

10

 NIHSS after 24 h

4

6

Not available

 Haemorrhagic transformation

No

No

Yes (Intraventricular haemorrhagic)

 Complication

None

Respiratory insufficiency (ARDS)

Respiratory insufficiency (ARDS)

 Outcome

Clinical recovery

Death

Death

  1. ALT alanine aminotransferase, aPTT activated partial thromboplastin time, ARDS acute respiratory distress syndrome, AST aspartate aminotransferase, COVID-19coronavirus disease 2019, CRP C-reactive protein, IV tPA intravenous tissue plasminogen activator, INR international normalized ratio, LDH lactate dehydrogenase, mRS modified ranking scale, NIHSS National Institutes of Health Stroke Scale, spo2oxygen saturation, PT prothrombin time